CAR T Cells for Solid Tumors: Armed and Ready to Go?

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Journal

• Publication date

  2014-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1097/PPO.0000000000000032PMID 24667962PMCID PMC4050065
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

  2013cited by this paper
• Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

  2013cited by this paper
• Reassessing target antigens for adoptive T cell therapy

  2013cited by this paper
• Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

  2013cited by this paper
• Chimeric Antigen Receptor T Cells with Dissociated Signaling Domains Exhibit Focused Antitumor Activity with Reduced Potential for Toxicity In Vivo

  2013cited by this paper
• Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma.

  2013cited by this paper
• Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

  2013cited by this paper
• Human T Cells Engineered To Express a Programmed Death 1/28 Costimulatory Retargeting Molecule Display Enhanced Antitumor Activity

  2013cited by this paper
• Depletion of stromal cells expressing fibroblast activation protein-α from skeletal muscle and bone marrow results in cachexia and anemia

  2013cited by this paper
• Gene-engineered T cells for cancer therapy

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• The basic principles of chimeric antigen receptor design.

  2013cited by this paper
• Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

  2013cited by this paper
• A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy.

  2012cited by this paper
• B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.

  2012cited by this paper
• BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

  2012cited by this paper
• Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies

  2012cited by this paper
• Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

  2012cited by this paper
• Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

  2012cited by this paper
• Tumor immunotherapy directed at PD-1.

  2012cited by this paper
• Epigenetic Modulation to Enable Antigen-specific T-cell Therapy of Colorectal Cancer

  2012cited by this paper
• Abstract 3500: T cells redirected against HER2 for the adoptive immunotherapy for HER2-positive osteosarcoma

  2012cited by this paper
• Interleukin 15 Provides Relief to CTLs from Regulatory T Cell–Mediated Inhibition: Implications for Adoptive T Cell–Based Therapies for Lymphoma

  2012influential reference
• Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.

  2011cited by this paper
• Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.

  2011cited by this paper
• Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

  2010cited by this paper
• Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

  2010cited by this paper
• T cells expressing constitutively active Akt resist multiple tumor-associated inhibitory mechanisms.

  2010cited by this paper
• TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.

  2010cited by this paper
• Prostate Stem Cell Antigen: A Jekyll and Hyde Molecule?

  2010cited by this paper
• Enhanced Tumor Trafficking of GD2 Chimeric Antigen Receptor T Cells by Expression of the Chemokine Receptor CCR2b

  2010cited by this paper
• Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

  2010cited by this paper
• Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4*

  2010cited by this paper
• CAR mechanics: driving T cells into the MUC of cancer.

  2009cited by this paper
• Cancer immunotherapy: co‐stimulatory agonists and co‐inhibitory antagonists

  2009cited by this paper
• Adoptive cell transfer: a clinical path to effective cancer immunotherapy

  2008cited by this paper
• Antitumor Activity of EBV-specific T Lymphocytes Transduced With a Dominant Negative TGF-β Receptor

  2008cited by this paper
• Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

  2008cited by this paper
• Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.

  2007cited by this paper
• Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes.

  2007cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

  2006cited by this paper
• Immune resistance orchestrated by the tumor microenvironment

  2006cited by this paper
• Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.

  2006cited by this paper
• Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis.

  2005cited by this paper
• Differential EphA2 epitope display on normal versus malignant cells.

  2003cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Redirecting Migration of T Cells to Chemokine Secreted from Tumors by Genetic Modification with CXCR2

  2002cited by this paper
• Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors

  2002cited by this paper
• Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

  2002cited by this paper
• A phage display selected Fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes

  2001cited by this paper
• GENETIC TREATMENT OF THE HAEMOGLOINOPATHIES: RECOMBINATIONS AND NEW COMBINATIONS

  1997cited by this paper

• A CD8αβ co-receptor modified to contain an intracellular CD28 signaling tail enhances TCR-engineered T cell function independent of solid-tumor-associated co-stimulatory ligands

  2026cites this paper
• Tumor cell-intrinsic stress states drive sensitivity to CAR T cell-therapy in pancreatic cancer

  2025cites this paper
• Discordant CAR-T cell signaling: implications of divergence from physiological T cell activation

  2025cites this paper
• Recent advances in adoptive cell therapy for cancer immunotherapy

  2025cites this paper
• How I Approach Ethical Considerations for Pediatric Phase I CAR T‐Cell Trials

  2025cites this paper
• Antitumor Activities by a Humanized Cancer‐Specific Anti‐Podoplanin Monoclonal Antibody humPMab‐117 Against Human Tumors

  2025cites this paper
• Emerging HER2 Targeting Immunotherapy for Cholangiocarcinoma

  2025cites this paper
• Immune-restoring CAR-T cells display antitumor activity and reverse immunosuppressive TME in a humanized ccRCC mouse model

  2024cites this paper
• Efficacy against Lung Cancer Is Augmented by Combining Aberrantly N-Glycosylated T Cells with a Chimeric Antigen Receptor Targeting Fragile X Mental Retardation 1 Neighbor.

  2024cites this paper
• Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4p230-239/HLA-A*02:01 complex.

  2024cites this paper
• CAR-T cell therapy: Advances in digestive system malignant tumors

  2024cites this paper
• Contemporary Approaches to Immunotherapy of Solid Tumors

  2024cites this paper
• Car T Cells in Solid Tumors: Overcoming Obstacles

  2024cites this paper
• Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects

  2024cites this paper
• Nanofibrous MultiDomain Peptide Hydrogels Provide T Cells a 3D, Cytocompatible Environment for Cell Expansion and Antigen-Specific Killing.

  2024cites this paper
• Suppression of the METTL3-m6A-integrin β1 axis by extracellular acidification impairs T cell infiltration and antitumor activity.

  2024cites this paper
• TET2 guards against unchecked BATF3-induced CAR T cell expansion

  2023cites this paper
• B7-H3 regulates anti-tumor immunity and promotes tumor development in colorectal cancer.

  2023cites this paper
• Disruption of SUV39H1-mediated H3K9 methylation sustains CAR T cell function.

  2023cites this paper
• A Description of Chimeric Antigen ReceptorModified T Cells in Cancer Immunotherapy

  2023cites this paper
• Tracking Adoptive Natural Killer Cells via Ultrasound Imaging Assisted with Nanobubbles.

  2023cites this paper
• Host Interactions with Engineered T-cell Micropharmacies

  2023cites this paper
• Cancer Cell Culture: The Basics and Two-Dimensional Cultures.

  2023cites this paper
• Cancer Immunotherapy: Where Next?

  2023cites this paper
• CAR-modified immune cells as a rapidly evolving approach in the context of cancer immunotherapies

  2023cites this paper
• Host-cell Interactions of Engineered T cell Micropharmacies

  2023cites this paper
• Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer.

  2023cites this paper
• The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies

  2023cites this paper
• Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy

  2023cites this paper
• Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma

  2023cites this paper
• Chimeric Antigen Receptor-Modified Immune Cells for Eradication of HIV Reservoirs

  2022cites this paper
• Development of CAR-T cells specifically targeting cancer stem cell antigen DNAJB8 against solid tumours

  2022cites this paper
• CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer

  2022cites this paper
• Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

  2022cites this paper
• CAR-T Cell Therapy for Solid Tumors: Are we Still That Far? a Systematic Review of Literature

  2022cites this paper
• Mapping CAR T-Cell Design Space Using Agent-Based Models

  2022cites this paper
• Targeting type I collagen for cancer treatment

  2022cites this paper
• Determination of the biodistribution of chimeric antigen receptor-modified T cells against CD19 in NSG mice.

  2022cites this paper
• Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors

  2022cites this paper
• Emerging trends in aggregation induced emissive luminogens as bacterial theranostics

  2021cites this paper
• Chimeric antigen receptor T-cells (CARs) in cancer treatment.

  2021cites this paper
• New Insights in Role of Cart-T Cell Therapy in Hematological

  2021cites this paper
• Pharmacokinetic and pharmacodynamic studies of CD19 CAR T cell in human leukaemic xenograft models with dual‐modality imaging

  2021cites this paper
• Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors

  2021cites this paper
• Cell therapies in the clinic

  2021cites this paper
• Nanomedicine‐Boosting Tumor Immunogenicity for Enhanced Immunotherapy

  2021cites this paper
• Non-viral transfection technologies for next-generation therapeutic T cell engineering.

  2021cites this paper
• Anti-angiogenic agents — overcoming tumour endothelial cell anergy and improving immunotherapy outcomes

  2021cites this paper
• The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice

  2021cites this paper
• Acellular Wharton’s Jelly, Potentials in T-Cell Subtypes Differentiation, Activation and Proliferation

  2020cites this paper
• Neoantigen-specific CD4+ T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy

  2020cites this paper
• Targeted Cellular Micropharmacies: Cells Engineered for Localized Drug Delivery

  2020cites this paper
• Correction: Differential Fuel Requirements of Human NK Cells and Human CD8 T Cells: Glutamine Regulates Glucose Uptake in Strongly Activated CD8 T Cells

  2020cites this paper
• Co-Expression of IL-7 Improves NKG2D-Based CAR T Cell Therapy on Prostate Cancer by Enhancing the Expansion and Inhibiting the Apoptosis and Exhaustion

  2020cites this paper
• Modelling the interplay between the CD4\documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$^{+}$$\end{document}+/CD8\docum

  2020cites this paper
• Optimizing Oncolytic Viral Design to Enhance Antitumor Efficacy: Progress and Challenges

  2020cites this paper
• Evaluation of targetable biomarkers for chimeric antigen receptor T-cell (CAR-T) in the treatment of pancreatic cancer: a systematic review and meta-analysis of preclinical studies

  2020cites this paper
• Cost of decentralized CAR T‐cell production in an academic nonprofit setting

  2020cites this paper
• Cancer immunotherapy: dawn of the death of cancer?

  2020cites this paper
• Immunotherapy in gastrointestinal cancer: The current scenario and future perspectives.

  2020cites this paper
• Anti-PSMA CAR-Engineered NK-92 Cells: An Off-the-Shelf Cell Therapy for Prostate Cancer

  2020cites this paper
• Immunotherapy for Renal Cell Carcinoma

  2020cites this paper
• Differential Fuel Requirements of Human NK Cells and Human CD8 T Cells: Glutamine Regulates Glucose Uptake in Strongly Activated CD8 T Cells

  2020cites this paper
• One-step in vivo metabolic labeling as a theranostic approach for overcoming drug-resistant bacterial infections

  2020cites this paper
• Combination Therapies in Solid Tumour Oncology

  2020cites this paper
• Advances and challenges in immunotherapy of small cell lung cancer

  2020cites this paper
• Determinants of Resistance to Checkpoint Inhibitors

  2020cites this paper
• CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead

  2020cites this paper
• The Vascular Disrupting Agent CA4P Improves the Antitumor Efficacy of CAR-T Cells in Preclinical Models of Solid Human Tumors.

  2020cites this paper
• Coating biomimetic nanoparticles with chimeric antigen receptor T cell-membrane provides high specificity for hepatocellular carcinoma photothermal therapy treatment

  2020cites this paper
• Strongly Activated CD8 T Cells Human CD8 T Cells: Glutamine Regulates Glucose Uptake in Differential Fuel Requirements of Human NK Cells and Lutz

  2020cites this paper
• Biologics vs. small molecules: Drug costs and patient access

  2020cites this paper
• Non-invasive monitoring of the kinetic infiltration and therapeutic efficacy of nanoparticle-labeled chimeric antigen receptor T cells in glioblastoma via 7.0-Tesla magnetic resonance imaging.

  2020cites this paper
• High‐Throughput Image Cytometry Detection Method for CAR‐T Transduction, Cell Proliferation, and Cytotoxicity Assays

  2020cites this paper
• Advances in the Management of Pediatric Sarcomas

  2020cites this paper
• MyD88/CD40 signaling retains CAR T cells in a less differentiated state

  2020cites this paper
• Organic/inorganic nanocomposites for cancer immunotherapy

  2020cites this paper
• Current Status and Future Perspective of Immunotherapy in Gastrointestinal Cancers

  2020cites this paper
• Biomaterial-assisted photoimmunotherapy for cancer.

  2020cites this paper
• A novel immunotherapy — the history of CAR T-cell therapy

  2019cites this paper
• Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety—A Systematic Review with Meta-Analysis

  2019cites this paper
• Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures

  2019cites this paper
• Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer

  2019cites this paper
• The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review

  2019cites this paper
• Frequency of Influenza-A-H1N1 in Patients with Community-Acquired Pneumonia Admitted to Loghman Hakim Hospital

  2019cites this paper
• Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance

  2019cites this paper
• Emerging Nano‐/Microapproaches for Cancer Immunotherapy

  2019cites this paper
• Gene Therapy: Current Applications and Future Possibilities.

  2019cites this paper
• TREM1/Dap12-based CAR-T cells show potent antitumor activity.

  2019cites this paper
• T cell immunotherapy enhanced by designer biomaterials.

  2019cites this paper
• A long way to the battlefront: CAR T cell therapy against solid cancers

  2019cites this paper
• Immunotherapy for hepatocellular carcinoma: recent advances and future perspectives

  2019cites this paper
• Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells

  2019cites this paper
• Conceptual Development of Immunotherapeutic Approaches to Gastrointestinal Cancer

  2019cites this paper
• Immunotherapeutic CAR T-Cell Engineering

  2019cites this paper
• Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors

  2019cites this paper
• A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors

  2019cites this paper
• Neoantigen-activated haploidentical T cell therapy for angioimmunoblastic T-cell lymphoma.

  2019cites this paper
• PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges.

  2019cites this paper
• Targeting cancers through TCR-peptide/MHC interactions

  2019cites this paper